William L. Cornog Acquires 12,500 Shares of Azenta, Inc. (NASDAQ:AZTA) Stock

Azenta, Inc. (NASDAQ:AZTA) Director William L. Cornog acquired 12,500 shares of the business’s stock in a transaction on Monday, November 18th. The shares were bought at an average price of $39.60 per share, for a total transaction of $495,000.00. Following the acquisition, the director now owns 14,755 shares in the company, valued at approximately $584,298. This trade represents a 554.32 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Azenta Price Performance

NASDAQ:AZTA traded up $0.54 during mid-day trading on Tuesday, reaching $40.91. The stock had a trading volume of 659,801 shares, compared to its average volume of 503,027. The business’s 50 day moving average is $45.44 and its 200 day moving average is $50.35. Azenta, Inc. has a fifty-two week low of $38.82 and a fifty-two week high of $69.16. The stock has a market cap of $2.00 billion, a P/E ratio of -13.59 and a beta of 1.48.

Azenta (NASDAQ:AZTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.08. Azenta had a positive return on equity of 1.03% and a negative net margin of 25.01%. The firm had revenue of $170.00 million for the quarter, compared to the consensus estimate of $169.66 million. During the same quarter in the prior year, the company posted $0.13 earnings per share. The firm’s revenue was down 1.2% on a year-over-year basis. Equities analysts expect that Azenta, Inc. will post 0.4 EPS for the current year.

Analyst Upgrades and Downgrades

AZTA has been the topic of several research analyst reports. Needham & Company LLC lowered their target price on Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Evercore ISI lowered their target price on Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $63.60.

Hedge Funds Weigh In On Azenta

A number of hedge funds have recently added to or reduced their stakes in AZTA. Hantz Financial Services Inc. acquired a new position in Azenta during the second quarter valued at approximately $30,000. Farther Finance Advisors LLC grew its holdings in Azenta by 20.0% during the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after purchasing an additional 256 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in Azenta by 150.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock valued at $84,000 after purchasing an additional 955 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Azenta during the first quarter valued at approximately $130,000. Finally, Acadian Asset Management LLC grew its stake in shares of Azenta by 24.7% in the first quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock worth $143,000 after acquiring an additional 471 shares during the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.